Next Article in Journal
The Signaling Role of CD40 Ligand in Platelet Biology and in Platelet Component Transfusion
Previous Article in Journal
Melatonin-Induced Temporal Up-Regulation of Gene Expression Related to Ubiquitin/Proteasome System (UPS) in the Human Malaria Parasite Plasmodium falciparum
Open AccessArticle

Discordance Rate of HER2 Status in Primary Gastric Carcinomas and Synchronous Lymph Node Metastases: A Multicenter Retrospective Analysis

1
Department of Human Pathology "Gaetano Barresi", Section of Anatomic Pathology, University of Messina, Messina 98123, Italy
2
Department "G.F. Ingrassia", Section of Anatomic Pathology, University of Catania, Catania 95123, Italy
3
Department of Medicine and Surgery, University of Salerno, Salerno 84131, Italy
4
Department of Diagnostic Medicine, Clinics and Public Health, Section of Pathologic Anatomy, University of Modena, Modena 41121, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2014, 15(12), 22331-22341; https://doi.org/10.3390/ijms151222331
Received: 5 November 2014 / Revised: 24 November 2014 / Accepted: 27 November 2014 / Published: 3 December 2014
(This article belongs to the Section Biochemistry)
Background: The assessment of human epidermal growth factor receptor 2 (HER2) gene amplification is essential in order to identify those patients affected by advanced gastric cancer who may benefit from Trastuzumab targeted therapy. Materials and Methods: With the aim to investigate the concordance rate in HER2 status between primary gastric carcinoma (GC) and synchronous lymphnode metastases, we investigated HER2 status in a cohort of 108 surgical formalin-fixed paraffin-embedded specimens of GC and matched synchronous metastatic lymph nodes collected from three different units of Anatomic Pathology in southern of Italy. Fleiss-Cohen weighted k statistics were used to assess the concordance rate of HER2 status. Results: HER2 amplification was observed in 17% of primary GCs and the overall concordance rate with corresponding nodal metastases was 90.74%. Changes in HER2 status between primary GC and matched synchronous metastases were evidenced in 10 (9.26%) cases. Of these, 6 cases were HER2 amplified in the primary GC and not amplified in the metastases, while 4 were HER2 not amplified in the primary tumour and amplified in the lymph node metastases. Conclusions: Although at present the simultaneous determination of HER2 in advanced gastric cancer and corresponding metastatic lymph nodes is not mandatory, the possibility that the synchronous metastases of GC have a different HER2 status from that of the primary tumour is of remarkable significance; Indeed this may have influence on the therapeutic management and prognosis of the patients. View Full-Text
Keywords: human epidermal growth factor receptor 2 (HER2); gastric cancer; synchronous lymph nodes; metastases; prognosis human epidermal growth factor receptor 2 (HER2); gastric cancer; synchronous lymph nodes; metastases; prognosis
Show Figures

Figure 1

MDPI and ACS Style

Ieni, A.; Barresi, V.; Caltabiano, R.; Caleo, A.; Bonetti, L.R.; Lanzafame, S.; Zeppa, P.; Caruso, R.A.; Tuccari, G. Discordance Rate of HER2 Status in Primary Gastric Carcinomas and Synchronous Lymph Node Metastases: A Multicenter Retrospective Analysis. Int. J. Mol. Sci. 2014, 15, 22331-22341.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop